Recent Finacing
Recent Raise
Aviceda is a Cambridge, MA clinical-stage biotech developing HALOS™ glycan‑coated nanoparticle therapeutics for ophthalmic and broader immunomodulatory indications, including intravitreal AVD‑104 targeting microglia/macrophage repolarization and complement inhibition.
